Deterministic Identity Testing for Sum of Read-Once Oblivious Arithmetic Branching Programs

A read-once oblivious arithmetic branching program (ROABP) is an arithmetic branching program (ABP) where each variable occurs in at most one layer. We give the first polynomial time whitebox identity test for a polynomial computed by a sum of constantly many ROABPs. We also give a corresponding blackbox algorithm with quasi-polynomial time complexity $n^{O(\log n)}$. In both the cases, our time complexity is double exponential in the number of ROABPs. ROABPs are a generalization of set-multilinear depth-$3$ circuits. The prior results for the sum of constantly many set-multilinear depth-$3$ circuits were only slightly better than brute-force, i.e. exponential-time. Our techniques are a new interplay of three concepts for ROABP: low evaluation dimension, basis isolating weight assignment and low-support rank concentration. We relate basis isolation to rank concentration and extend it to a sum of two ROABPs using evaluation dimension (or partial derivatives).Comment: 22 pages, Computational Complexity Conference, 201

Identity Testing for Constant-Width, and Commutative, Read-Once Oblivious ABPs

We give improved hitting-sets for two special cases of Read-once Oblivious Arithmetic Branching Programs (ROABP). First is the case of an ROABP with known variable order. The best hitting-set known for this case had cost (nw)^{O(log(n))}, where n is the number of variables and w is the width of the ROABP. Even for a constant-width ROABP, nothing better than a quasi-polynomial bound was known. We improve the hitting-set complexity for the known-order case to n^{O(log(w))}. In particular, this gives the first polynomial time hitting-set for constant-width ROABP (known-order). However, our hitting-set works only over those fields whose characteristic is zero or large enough. To construct the hitting-set, we use the concept of the rank of partial derivative matrix. Unlike previous approaches whose starting point is a monomial map, we use a polynomial map directly. The second case we consider is that of commutative ROABP. The best known hitting-set for this case had cost d^{O(log(w))}(nw)^{O(log(log(w)))}, where d is the individual degree. We improve this hitting-set complexity to (ndw)^{O(log(log(w)))}. We get this by achieving rank concentration more efficiently

A comparison of toxicity profile of gemcitabine monotherapy versus etoposide/cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer

Background: Lung cancer is the leading cause of cancer deaths globally in which about 40% patients reporting in advanced stage disease. Both platinum and non platinumcombinations have been shown to be equally efficacious as initial first-line treatment of advanced non-small cell lung cancer (NSCLC), however because of the toxicity of cisplatin, combination treatment can only be administered to a minority of patients in good general health. Gemcitabine could be combined with one of the other new agents to create novel non-platinum-doublet combinations with efficacy and/or toxicity profile superior to that of standard platinum based combinations. Hence, this study was conducted to compare the toxicity profiles of gemcitabine monotherapy and the cisplatin/etoposide combination therapy.Methods: This was a randomized prospective study, which included 96 patients selected on the basis of histologically or cytologically confirmed Stage III B or IV of NSCLC. Study was divided into two arms-Arm A received gemcitabine monotherapy in a dose of 1000 mg/m2 on day 1 and 5 of the cycle andrepeated after every 3 weeks while Arm B received cisplatin (25 mg/m2 on day 1, 2 and 3) + etoposide (100 mg/m2). Patient were evaluated for adverse events by following World Health Organization grading of toxicity.Results: Out of the 96 patients enrolled in the study, 74 (77.0%) patients were eligible and were analyzed. Of these, 36 (37.5%) patients belonged to Arm A and 38 (39.5%) to Arm B. Transient vomiting (45.8% vs. 37.5%), leukopenia (33.3% vs. 8.3%) were seen more in Arm A, while thrombocytopenia (33.3% vs. 12.5%), patchy hair loss (68.4% vs. 16.6%) was seen more in Arm B. Nephrotoxicity was seen almost similarly in both the groups.Conclusions: Single-agent gemcitabine appears to have a safer toxicity profile than the combination cisplatin-etoposide in the first-line chemotherapy of advanced NSCLC. With less toxic anticancer drugs like gemcitabine, the physician now has greater choice in choosing treatment, which can have better effect on the patients concerned

Protective Role of Ashwagandha Leaf Extract and Its Component Withanone on Scopolamine-Induced Changes in the Brain and Brain-Derived Cells

BACKGROUND:Scopolamine is a well-known cholinergic antagonist that causes amnesia in human and animal models. Scopolamine-induced amnesia in rodent models has been widely used to understand the molecular, biochemical, behavioral changes, and to delineate therapeutic targets of memory impairment. Although this has been linked to the decrease in central cholinergic neuronal activity following the blockade of muscarinic receptors, the underlying molecular and cellular mechanism(s) particularly the effect on neuroplasticity remains elusive. In the present study, we have investigated (i) the effects of scopolamine on the molecules involved in neuronal and glial plasticity both in vivo and in vitro and (ii) their recovery by alcoholic extract of Ashwagandha leaves (i-Extract). METHODOLOGY/PRINCIPAL FINDINGS:As a drug model, scopolamine hydrobromide was administered intraperitoneally to mice and its effect on the brain function was determined by molecular analyses. The results showed that the scopolamine caused downregulation of the expression of BDNF and GFAP in dose and time dependent manner, and these effects were markedly attenuated in response to i-Extract treatment. Similar to our observations in animal model system, we found that the scopolamine induced cytotoxicity in IMR32 neuronal and C6 glioma cells. It was associated with downregulation of neuronal cell markers NF-H, MAP2, PSD-95, GAP-43 and glial cell marker GFAP and with upregulation of DNA damage--γH2AX and oxidative stress--ROS markers. Furthermore, these molecules showed recovery when cells were treated with i-Extract or its purified component, withanone. CONCLUSION:Our study suggested that besides cholinergic blockade, scopolamine-induced memory loss may be associated with oxidative stress and Ashwagandha i-Extract, and withanone may serve as potential preventive and therapeutic agents for neurodegenerative disorders and hence warrant further molecular analyses

Assessing Implications of Telehealth Apps’ Privacy Policies and Terms of service for Users

Without a doubt, the widespread reliance on telehealth increased during the Covid-19. Telehealth allows users to receive healthcare services from the comfort of their own homes. Simultaneously, healthcare data breaches skyrocket due to hacking targeting telehealth more. Amidst this, users' concerns for the privacy and security of their personal/medical information are genuine. Privacy policy documents, which describe an organization's practices regarding data collection, use, and disclosure of consumer information, have been criticized as too weak or convoluted. The study aims to evaluate how these telehealth applications communicate with users via their privacy policies and terms of service documents. To accomplish this, I intended to use a descriptive study design to conduct a thorough qualitative analysis of the 14 telehealth app documents. In the results, some points focus on platforms providing no guarantee about healthcare providers and platforms failing to meet high standards for information security. In conclusion, the focus is to provide more comprehensive standards and regulations to ensure strong privacy and security safeguards for telehealth and all electronic consumer data.Master of ScienceMTOPUniversity of Michiganhttp://deepblue.lib.umich.edu/bitstream/2027.42/177159/1/Saxena_AssessingImplicationsofTelehealthAppsPrivacyPoliciesandTermsofserviceforUsers_2022.pdfDescription of Saxena_AssessingImplicationsofTelehealthAppsPrivacyPoliciesandTermsofserviceforUsers_2022.pdf : Saxena - Main File for Final Master's Thesi

Natural antioxidants synergistically enhance the anticancer potential of AP9-cd, a novel lignan composition from Cedrus deodara in human leukemia HL-60 cells

Antioxidants have been used as adjuvant with anticancer therapy to synergize the potential of the antineoplastic therapeutics. Based on the fact, we have studied the effect of three natural antioxidants curcumin, silymarin and acteoside on AP9-cd (standardized lignan composition from Cedrus deodara) induced cytotoxicity in human leukemia HL-60 cells. The antioxidant potential of individual test compounds was first evaluated with ferric reducing antioxidant power (FRAP) test, which revealed that all four molecules behave as antioxidants. The apoptotic potential of AP9-cd was significantly enhanced in HL-60 cells in the presence of curcumin, silymarin and acteoside. It was confirmed by using various models like MTT assay, DNA fragmentation, nuclei condensation, sub-Go DNA population, Annexin-V-FITC binding, ROS depletion and immunoblotting in HL-60 cells. AP9-cd and individual antioxidants alone at low doses (10�g and 10�M, respectively) have meager or no cytotoxicity in HL-60 cells, whereas in mutual combinations, there were 2–3 times enhancement in Annexin-V-FITC and sub-Go DNA population. Moreover, prominent DNA ladders were observed at low doses of AP9-cd in combinations with various antioxidants. The Hoechst staining of the nucleus also revealed the same results for the HL-60 cells treated with AP9-cd and different antioxidants. The molecular diagnostics revealed that the combinations induced a strong antioxidant effect which was correlated with the downregulation of NF-�B expression in the nucleus. Out of the three antioxidants, curcumin was found to be more potent than acteoside and silymarin in terms of enhancing the apoptotic potential of AP9-cd. These results propose an important role of natural antioxidant as adjuvant to enhance the anticancer potential of AP9-cd and more likely other anti-neoplastic therapeutics

Natural antioxidants synergistically enhance the anticancer potential of AP9-cd, a novel lignan composition from Cedrus deodara in human leukemia HL-60 cells

Antioxidants have been used as adjuvant with anticancer therapy to synergize the potential of the antineoplastic therapeutics. Based on the fact, we have studied the effect of three natural antioxidants curcumin, silymarin and acteoside on AP9-cd (standardized lignan composition from Cedrus deodara) induced cytotoxicity in human leukemia HL-60 cells. The antioxidant potential of individual test compounds was first evaluated with ferric reducing antioxidant power (FRAP) test, which revealed that all four molecules behave as antioxidants. The apoptotic potential of AP9-cd was significantly enhanced in HL-60 cells in the presence of curcumin, silymarin and acteoside. It was confirmed by using various models like MTT assay, DNA fragmentation, nuclei condensation, sub-Go DNA population, Annexin-V-FITC binding, ROS depletion and immunoblotting in HL-60 cells. AP9-cd and individual antioxidants alone at low doses (10�g and 10�M, respectively) have meager or no cytotoxicity in HL-60 cells, whereas in mutual combinations, there were 2–3 times enhancement in Annexin-V-FITC and sub-Go DNA population. Moreover, prominent DNA ladders were observed at low doses of AP9-cd in combinations with various antioxidants. The Hoechst staining of the nucleus also revealed the same results for the HL-60 cells treated with AP9-cd and different antioxidants. The molecular diagnostics revealed that the combinations induced a strong antioxidant effect which was correlated with the downregulation of NF-�B expression in the nucleus. Out of the three antioxidants, curcumin was found to be more potent than acteoside and silymarin in terms of enhancing the apoptotic potential of AP9-cd. These results propose an important role of natural antioxidant as adjuvant to enhance the anticancer potential of AP9-cd and more likely other anti-neoplastic therapeutics